Alder BioPharmaceuticals, Inc. is set to present updated findings from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, a novel therapeutic antibody for migraine prevention, at the American Headache Society (AHS) annual scientific meeting. The presentations will cover a range of data, including efficacy outcomes from PROMISE 2 for chronic migraine patients who received two quarterly infusions of eptinezumab. Key outcomes will focus on the reduction of monthly migraine days, early onset of activity, and responder rates after treatment.
Eptinezumab's potential as a new treatment option is supported by data showing significant reductions in migraine risk from day one, sustained through 12 weeks, and further improvements after multiple infusions. The PROMISE 1 trial's year-long data on episodic migraine patients and the Short-Form Health Survey Scores from PROMISE 2, assessing quality of life, will also be highlighted.
The presentations at the AHS meeting will include late-breaking studies, platform presentations, and poster presentations, featuring insights from leading researchers in the field. These sessions aim to provide a comprehensive overview of eptinezumab's impact on migraine prevention, including its ability to reduce migraine activity and achieve high responder rates among patients.
Eptinezumab represents a significant advancement in migraine treatment, offering hope to millions of patients worldwide who suffer from this debilitating condition. With its unique mechanism of action and promising clinical trial results, eptinezumab could become a key therapeutic option for migraine prevention, addressing the significant unmet need for effective and well-tolerated treatments.
